NEW YORK (GenomeWeb) – GlaxoSmithKline and 23andMe announced today that they have signed a four-year drug discovery collaboration deal in which both partners will initially contribute 50 percent of the funding, will have the ability to advance targets together or independently, and will share in the proceeds from any new drugs developed within the partnership.

Additionally, GSK said it has made a $300 million equity investment in 23andMe.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.